Xspray Pharma AB (publ) (XSPRAY.ST)
Xspray Pharma AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, AB, SE. The stock last traded at $9.37, up 1.74% on the session, giving a market capitalisation of $444.3M. Its beta of -0.03 implies it has historically moved less than the broad market.
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Xspray Pharma AB (publ) is most often compared with the following Healthcare names: